Teleflex (NYSE:TFX) Releases FY 2025 Earnings Guidance

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Teleflex (NYSE:TFX - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 13.900-14.300 for the period, compared to the consensus estimate of 13.406. The company issued revenue guidance of $3.3 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Teleflex Price Performance

NYSE:TFX traded down $3.63 during trading hours on Friday, hitting $115.87. The company's stock had a trading volume of 642,835 shares, compared to its average volume of 535,501. The stock has a fifty day simple moving average of $118.73 and a 200-day simple moving average of $137.16. The company has a market capitalization of $5.12 billion, a P/E ratio of 27.26, a PEG ratio of 1.87 and a beta of 1.08. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.32. Teleflex has a twelve month low of $108.90 and a twelve month high of $249.90.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%. The business had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. During the same period last year, the firm posted $3.42 earnings per share. Teleflex's revenue was up 4.2% compared to the same quarter last year. On average, analysts anticipate that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 15th. Shareholders of record on Friday, August 15th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Friday, August 15th. Teleflex's dividend payout ratio is presently 32.00%.

Analyst Upgrades and Downgrades

TFX has been the topic of several recent research reports. Morgan Stanley cut their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a report on Monday, May 5th. Mizuho increased their price target on Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a report on Friday. Royal Bank Of Canada increased their price target on Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a report on Friday. Wells Fargo & Company decreased their price target on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a report on Friday. Finally, Wall Street Zen upgraded Teleflex from a "hold" rating to a "strong-buy" rating in a report on Saturday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $160.13.

Hedge Funds Weigh In On Teleflex

An institutional investor recently raised its position in Teleflex stock. Empowered Funds LLC grew its holdings in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 15.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,684 shares of the medical technology company's stock after buying an additional 230 shares during the quarter. Empowered Funds LLC's holdings in Teleflex were worth $233,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.